Get started
Author

Emerson Logan

ORCID: 0009-0001-7639-3192
Observed ORCID: 0009-0001-7639-3192
OpenAlex ID: A5092717037
Timing of Toxicities and Non-Relapse Mortality Following CAR T Therapy in Myeloma
2024 · William Wesson, Danai Dima, et al. · Transplantation and Cellular Therapy · 41
Safety and efficacy of eltrombopag in patients with post‐ CAR T cytopenias
2023 · William Wesson, Nausheen Ahmed, et al. · European Journal Of Haematology · 15
PDF
TACTUM: Trends in Access to Cellular Therapies in Multiple Myeloma, Perspectives of Treating Versus Referring Physicians
2024 · Rawan Atallah, Nausheen Ahmed, et al. · Transplantation and Cellular Therapy · 8
Global Access to Multiple Myeloma Therapies
2025 · Rawan Atallah, Yara Shatnawi, et al. · JCO Global Oncology · 6
Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab‐naïve relapsed multiple myeloma
2024 · Danai Dima, Razan Mansour, et al. · European Journal Of Haematology · 5
PDF
Balancing Monitoring and Access: Optimal Duration of Monitoring for CD19 and BCMA CART Recipients for Lymphoma and Myeloma
2023 · William Wesson, Aliya Rashid, et al. · Blood · 4
The Glass Wall: Gendered Authorship Disparities in CD 19 and BCMA CAR-T Clinical Trials for Lymphoma and Myeloma
2024 · Aroog Khaliq, William Wesson, et al. · Clinical Lymphoma Myeloma & Leukemia · 3
The GLAMM1 Study - Global Access to Myeloma Medications: Potential Barriers to Chimeric Antigen Receptors (CART) and T-Cell-Engaging Bispecific Antibodies (TCE) Globally
2024 · Rawan Atallah, Yara Shatnawi, et al. · Transplantation and Cellular Therapy · 3
Avascular Necrosis (AVN) Outcomes in Allogeneic Stem Cell Transplant Recipients
2024 · Dania Shoaib, Aroog Khaliq, et al. · Blood · 1
A Multicenter Experience: Duration of Mandatory CRS and Icans Monitoring for Myeloma and Lymphoma CAR-T Recipients
2024 · William Wesson, Danai Dima, et al. · Transplantation and Cellular Therapy · 1
Use of Eltrombopag for Post-CAR T Cytopenias: A Multi-Institutional Experience
2023 · William Wesson, Nausheen Ahmed, et al. · Blood · 1
Avascular Necrosis (AVN) Outcomes in Allogeneic Stem Cell Transplant Recipients
2025 · Dania Shoaib, Aroog Khaliq, et al. · Transplantation and Cellular Therapy
The TACTUM23 Study: Access to Cellular Therapies in Multiple Myeloma: Perspectives of Treating Versus Referring Physicians in 2023
2024 · Rawan Atallah, Md Saiful Islam Saif, et al. · Transplantation and Cellular Therapy
The Glass Wall: Gendered Authorship Disparities in in CD 19 and BCMA CAR-T Clinical Trials for Lymphoma and Myeloma.
2024 · Aroog Khaliq, William Wesson, et al. · Transplantation and Cellular Therapy
The Glass Wall: Gendered Authorship Disparities in Cd 19 and Bcma Car-T Clinical Trials for Lymphoma and Myeloma
2024 · Aroog Khaliq, William Wesson, et al. · SSRN Electronic Journal
The Glass Wall: Gendered Authorship Disparities in in CD 19 and BCMA CAR-T Clinical Trials for Lymphoma and Myeloma
2023 · Aroog Khaliq, William Wesson, et al. · Blood
PDF
Efficacy and Safety of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in Daratumumab-Naïve Relapsed Multiple Myeloma: Multicenter Real-World Experience
2023 · Razan Mansour, James A Davis, et al. · Blood
PDF
CT-216 Safety and Efficacy of Eltrombopag in Patients With Post-CAR T Cytopenias: Real-World Experience
2023 · William Wesson, Nausheen Ahmed, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: CT-216 Safety and Efficacy of Eltrombopag in Patients With Post-CAR T Cytopenias: Real-World Experience
2023 · William Wesson, Nausheen Ahmed, et al. · Clinical Lymphoma Myeloma & Leukemia
PDF
Works count: 19
Citation count: 88
H-index: 5
I10-index: 2
Year
Topic
Type